sc-raav2.5il-1ra
Gene therapyexperimental
Clinical trial activity
5 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT02790723)
Timeline
Indications
Mechanism of action
- Interleukin-1 receptor type 1Supplementation
IL1R1 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1201570 ↗
Also known as
- anakinra
- sc-raav2.5il-1ra
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05835895 | Phase 1 | Jun 12, 2023 | California Institute for Regenerative Medicine (CIRM), Genascence Corporation |
| NCT03182426 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2017 | Alberta Innovates Health Solutions, University of Alberta |
| NCT03141983 | Phase 2 | Jun 1, 2017 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), University of Pennsylvania |
| NCT03062176 | Phase 2 | Apr 3, 2017 | Virginia Commonwealth University |
| NCT02790723 | Phase 1 | Jan 1, 2017 | Mayo Clinic |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alberta Innovates Health Solutions | Academic/Hospital | 1 | 0 | 1 | 2017 |
| California Institute for Regenerative Medicine (CIRM) | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Genascence Corporation | For profit | 1 | 1 | 1 | 2023 |
| Mayo Clinic | Academic/Hospital | 1 | 1 | 1 | 2017 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 0 | 1 | 2017 |
| University of Alberta | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 1 | 1 | 2017 |
8 organizations
Page 1 / 1